Compare JTAI & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JTAI | ALZN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 3.9M |
| IPO Year | N/A | 2021 |
| Metric | JTAI | ALZN |
|---|---|---|
| Price | $9.04 | $1.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $80.00 | $28.00 |
| AVG Volume (30 Days) | ★ 161.8K | 46.7K |
| Earning Date | 05-15-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.84 |
| 52 Week High | $10.41 | $4.30 |
| Indicator | JTAI | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 66.84 | 53.10 |
| Support Level | $6.03 | $1.03 |
| Resistance Level | $9.24 | $1.25 |
| Average True Range (ATR) | 0.69 | 0.08 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 88.29 | 55.17 |
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.